Detalhe da pesquisa
1.
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.
Hepatology
; 54(3): 772-80, 2011 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-21626525
2.
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Hepatology
; 53(2): 389-95, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21274861
3.
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Gastroenterology
; 139(3): 821-7, 827.e1, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20621700
4.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Hepatology
; 49(2): 358-63, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19072829
5.
IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.
Antivir Ther
; 16(8): 1309-16, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22155912